Why CA2+ antagonists will be most useful before or during myocardial ischaemia and not after infarction has been established

• Hugenholtz, P.G.
• Serruys, P.W.J.C.
• Fleckenstein, A.
• Nayler, W.

January 1986
Article

Related Files
View PDF Version (1312.pdf, 7.1MB)
Redirect to Publishers version (Publishers version.url.txt, 51 bytes)

• Animals
• Comparative Study
• Human
• Time Factors
• 21829-25-4 (Nifedipine)
• Drug Therapy, Combination
• 0 (Adrenergic beta-Antagonists)
• 0 (Calcium Channel Blockers)
• Coronary Vessels/drug effects
• Calcium Channel Blockers/pharmacology/*therapeutic use
• Adrenergic beta-Antagonists/administration & dosage
• Angina, Unstable/drug therapy
• Coronary Disease/*drug therapy/pathology/physiopathology
• Heart/drug effects/physiopathology
• Myocardial Infarction/drug therapy
• Myocardium/metabolism/ultrastructure
• Nifedipine/pharmacology